The data in this paper is related to the research article entitled "Thrombin-activatable fibrinolysis inhibitor Thr325Ile polymorphism and plasma level in breast cancer: A pilot study" (Fawzy et al., 2015) [1]. Many emerging studies have begun to unravel the pathophysiologic role of the fibrinolytic system in breast cancer (BC) progression (Zorio et al., 2008) [2]. Activation of the fibrinolytic plasminogen/plasmin system results in degradation of protein barriers, thereby mediating cell migration essential for tumor growth, angiogenesis, and dissemination (Castellino and Ploplis, 2005) [3]. In the current study, in silico data analysis of ThrombinActivatable Fibrinolysis Inhibitor (TAFI) gene and protein has been done. Data have been retrieved from several databases mentioned in details in the text. Determination and analysis of the structural and functional impact of TAFI and its expression could help elucidate the contribution of the TAFI pathway to acquired hemostatic dysfunction and will form the basis of potential therapeutic strategies to manipulate this pathway. An inhibition of TAFI (e.g. by FXI inhibitors) will offer the therapeutic possibilities to improve the decreased fibrinolysis and increase the efficiency of fibrinolytic therapy in thrombotic disorders including cancer.
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Value of the data
This data provides a comprehensive in silico analysis of the structural and functional characterization of TAFI and its expression.
The data are useful for understanding the effect of TAFI variants on its structure and function. This data may provide insight for determining the role of future drug treatment to inhibit TAFI function especially in cancer cases.
1. Data, experimental design, materials and methods
TAFI activation and function
Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) represents the molecular link between the coagulation and fibrinolytic pathways [4, 5] (Fig. 1 ). Human TAFI, also known as carboxypeptidase basic (CPB2) and unstable (CPU), is a procarboxypeptidase enzyme and a member of the family of metallocarboxypeptidases that carries a zinc ion essential for catalytic action and preferentially cleaves the carboxyl-terminal peptide bonds of basic amino acids [6, 7] . TAFI protein is encoded by TAFI gene at 13q14.11 spanning about 58 kb of genomic DNA. It has 2 different transcripts of 1717 and 1655 base pairs due to alternative splicing (Fig. 2) . TAFI protein is synthesized by the liver as a single chain glycoprotein zymogen with a molecular weight of 60.0 kDa, circulates in the plasma in an inactive form bound to plasminogen [8] [9] . TAFI protein has 3 main domains; signal peptide of 22 residues, activation peptide (propeptide domain) of 92 amino acids, and catalytic chain of 309 residues (Fig. 3) . Crystal structure of TAFI revealed that the precursor protein, in the zymogen form, exists as a globular domain followed by an extended alpha-helix. It maintains its stability via the interaction of the activation peptide with a highly dynamic region from residues 318-372 in the catalytic domain [10] . Dissociation of the activation peptide increases the dynamic flap mobility of this 55 residue segment and consequently results in increased plasticity of the entire catalytic chain, complete unfolding, and exposure of the cryptic thrombin-cleavage site present at Arg324 [11] (Fig. 4) .
TAFI activity is generated during the blood clotting process via binding to thrombin, thrombinthrombomodulin complex, or plasmin, which in turn cleave TAFI protein at Arg114 (residue Arg92 after removal of the signal peptide) into N-terminal activation peptide and catalytic domains, leading to exposure of the active site cleft of activated TAFI (TAFIa) [10, 13] . The rate of thrombin catalyzed activation of TAFI is increased by 1250 fold by formation of a ternary complex with thrombomodulin (T-TM-TAFI) rather than the binary thrombin-TAFI complex (T-TAFI) [14] . TAFIa exhibits carboxypeptidase activity by removal of the C-terminal lysine and arginine residues from fibrin that are essential for binding and activation of plasminogen. Consequently, removal of these residues leads to less plasmin formation and subsequently down-regulates fibrinolysis and stabilizing the clots [15] . TAFI is unique among carboxypeptidases in that the TAFIa decays spontaneously into the inactive form of TAFI (TAFIai) through a temperature-dependent conformational change, thus attaining a short half-life, a property that is crucial for its role in controlling blood clot lysis [10, 16] . In addition to the role of TAFI in fibrinolysis regulation, TAFIa also plays a role in the modulation of inflammation through down-regulation of pericellular plasminogen activation and inactivation of the inflammatory peptides bradykinin and anaphylatoxins C3a and C5a [16] . Other biological functions of TAFI were elucidated; including cell migration, blood pressure and tissue repair [4] (Fig. 5) . Coagulation and fibrinolytic cascades. Ca, calcium; FDPs, fibrin degradation product; PAI-1 and PAI-2; plasminogen activator inhibitors; PL, phospjolipids; TAFI, thrombin activatable fibrinolysis inhibitor; TF, tissue factor; tPA, tissue plasminogen activator; uPA, urokinase plasminogen activator. Both intrinsic and extrinsic pathways involved with a series of sequential cleavage events which ends with thrombin activation from its zymogen prothrombin. Active thrombin can then catalyze the polymerization of fibrin monomers which converts soluble fibrinogen into an insoluble fibrin matrix. As the clot forms, circulating red blood cells, white blood cells, and platelets become incorporated into its structure. In addition, fibrin becomes cross-linked providing further structural stability. On the other hand, fibrinolysis, through the action of plasmin, prevents unnecessary accumulation of intravascular fibrin and enables the removal of thrombi. Plasmin is generated from the zymogen plasminogen on the surface of the fibrin clot by either tissue plasminogen activator (tPA) or urokinase (uPA) [3] . Proteolysis of fibrin gives rise to soluble fibrin degradation products (FDPs), some of which have immunomodulatory and chemotactic functions [2] . The coagulation and fibrinolytic systems are highly regulated and interrelated through mechanisms that insure balanced hemostasis. The molecular linker between the two processes, TAFI, is first produced as a proenzyme that is activated by thrombin or plasmin generated during the coagulation cascade. The active form, TAFIa, inhibits fibrinolysis by cleaving off C-terminal lysine residues from partially degraded fibrin. These residues act as a template onto which both tPA and plasminogen bind thereby enhancing the catalytic efficiency of plasmin formation. Cleavage of these basic amino acids downregulates fibrinolysis.
TAFI deregulation in cancer
The plasma concentration of TAFI appears to be under the control of genetic factors and nongenetic factors [16] . Several diseases, including diabetes, kidney transplantation, hypertension, nephritic syndrome, insulin resistance, obesity, and inflammatory bowel disease, have been shown to be positively associated with plasma TAFI levels [17] . In cancer, Expression Atlas databases reported over-expression of TAFI levels in breast, ovarian, and hepatic cancer cell lines [18, 19] . Plasma levels of TAFI were found to be significantly increased in various types of cancer; including BC [1, 20] , lung cancer [21] , gastric carcinoma [22] , and multiple myeloma [23] . In addition, higher TAFI levels were associated with a more advanced cancer stage [1, 23] . The mechanism of increased circulating levels of TAFI in cancer patients remains to be fully explored. Two hypotheses were proposed; inflammatory cytokines induced by cancer cells may stimulate the production and secretion of TAFI from liver or vascular endothelial cells and thus increase its circulatory levels. Besides, malignant cells may also be figure. (B) Q96IY4-2 isoform. Same sequence as isoform 1 except have missing 37 amino acids equivalent for exon 7 sequence from 198 to 234 residues and sequence distal to 384 till the end of isoform 1 is replaced by another 14 amino acids thus lacking the active site E385 essential for catalytic activity. (C) A0A087WSY5 protein share characteristics of Q96IY4-1 and Q96IY4-2. It has an identical sequence to isoform 1 except amino acids of exon 7 which are missing as in isoform 2. (Data source: UniProtKB for Q96IY4 and A0A087WSY5, last modified on July 22, 2015). A blue line indicates binding interaction; a grey line with green arrow shows proteins which activate TAFI protein; black edge states for reaction evidence. The string global score (confidence score) was adjusted to be greater than 0.95. CPE, carboxypeptidase E; CPN1, carboxypeptidase N, polypeptide 1; CPN2, carboxypeptidase N, polypeptide 2; F2, coagulation factor II (thrombin); INS, insulin; PLG, plasminogen; PPARA, peroxisome proliferator-activated receptor alpha; Ligandactivated transcription factor; PROC, protein C (inactivator of coagulation factors Va and VIIIa); PSMA6, proteasome (prosome, macropain) subunit, alpha type, 6; UBE2A, ubiquitin-conjugating enzyme E2A (http://string.embl.de/). a direct source of TAFI in cancer patients. Secretion of TAFI from cancer cells may increase intratumoral fibrin deposition and thus promotes tumor cell growth and dissemination [24] .
Functional genetic variants of TAFI gene
According to several databases, TAFI gene contains multiple variants; all are rare with minor allele frequencies (MAF) of less than 0.001 except two common natural variants rs3742264 and rs1926447 at positions 46073959 and 46055809 with MAF of 0.31 (T) and 0.22 (A), respectively, Fig. 6 . Although our in silico analysis predicted these two coding SNPs to be functionally neutral using polymorphism phenotyping (PolyPhen) version 2 and MutPred web-based programs [25] , however, evidences from prior studies revealed that Thr169 and Thr347 are associated with higher plasma TAFI levels [5, 26] and that the 1040 T for C substitution results in a TAFIa species with a prolonged half-life at 37°C [27] . Possibly, this increased stability of TAFIa compensates for the decreased levels of the protein [5] . 
